| 5.39 -0.06 (-1.1%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.35  |
1-year : | 9.82 |
| Resists | First : | 7.15 |
Second : | 8.4 |
| Pivot price | 6.19 |
|||
| Supports | First : | 5.11 |
Second : | 4.25 |
| MAs | MA(5) : | 5.62 |
MA(20) : | 6.44 |
| MA(100) : | 8.05 |
MA(250) : | 10.92 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 9.3 |
D(3) : | 10.1  |
| RSI | RSI(14): 23 |
|||
| 52-week | High : | 22.75 | Low : | 5.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TVTX ] has closed above bottom band by 11.8%. Bollinger Bands are 17.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.51 - 5.55 | 5.55 - 5.58 |
| Low: | 5.03 - 5.08 | 5.08 - 5.11 |
| Close: | 5.33 - 5.4 | 5.4 - 5.45 |
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Thu, 25 Apr 2024
Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasted to Post FY2028 Earnings of $4.29 Per Share - MarketBeat
Wed, 24 Apr 2024
Travere stock gains on EU nod for Filspari (NASDAQ:TVTX) - Seeking Alpha
Wed, 24 Apr 2024
Brokerages Set Travere Therapeutics, Inc. (NASDAQ:TVTX) PT at $17.85 - MarketBeat
Wed, 24 Apr 2024
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the ... - PR Newswire
Sat, 20 Apr 2024
Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop - Simply Wall St
Wed, 17 Apr 2024
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 115.2 (%) |
| Shares Short | 10,600 (K) |
| Shares Short P.Month | 10,260 (K) |
| EPS | -5.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.66 |
| Profit Margin | -76.7 % |
| Operating Margin | -183.9 % |
| Return on Assets (ttm) | -32.3 % |
| Return on Equity (ttm) | -308.9 % |
| Qtrly Rev. Growth | 53.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.9 |
| EBITDA (p.s.) | -4.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -280 (M) |
| Levered Free Cash Flow | -179 (M) |
| PE Ratio | -1.07 |
| PEG Ratio | -0.1 |
| Price to Book value | 2.02 |
| Price to Sales | 2.82 |
| Price to Cash Flow | -1.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|